C. Suárez Rodríguez

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial

Brian I. Rini, Tanya B. Dorff, Paul Elson et al. · The Lancet Oncology · 2016 · 250 citations · Full text

Urology, Metastatic Renal-cell Carcinoma, Genitourinary Cancer +5

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study

Begoña Pérez‐Valderrama, Jóse Ángel Arranz Arija, Ángel Rodríguez Sánchez et al. · Annals of Oncology · 2015 · 36 citations · Full text

Urology, Spazo Study, Genitourinary Cancer +7

Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy: Results from cohort 2 of the COSMIC-021 study.

Sumanta K. Pal, Neeraj Agarwal, Yohann Loriot et al. · Journal of Clinical Oncology · 2020 · 26 citations

Platinum-containing Chemotherapy, Pharmacotherapy, Metronomic Chemotherapy +18

CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma.

Sumanta K. Pal, Laurence Albigès, C. Suárez Rodríguez et al. · Journal of Clinical Oncology · 2021 · 24 citations

Anti-pd-l1 Mab, Urology, Tps370 Background +14

IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)

Thomas Powles, David F. McDermott, Brian I. Rini et al. · Annals of Oncology · 2017 · 20 citations · Full text